Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

Last updated: February 14, 2012
Sponsor: Bausch & Lomb Incorporated
Overall Status: Completed

Phase

2/3

Condition

Eye Disorders/infections

Conjunctivitis, Bacterial

Allergy

Treatment

N/A

Clinical Study ID

NCT00972777
603
  • Ages > 1
  • All Genders

Study Summary

This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subjects who are at least one year of age.

  • Subjects who have a clinical diagnosis of acute bacterial conjunctivitis.

  • Subjects who are willing to discontinue contact lens wear for the duration of thestudy.

Exclusion

Exclusion Criteria:

  • Subjects who have any uncontrolled systemic disease or debilitating disease.

  • Subjects with known sensitivity or contraindications to besifloxacin, fluoroquinolonesor any ingredients in study drugs.

  • Subjects who are expected to require treatment with any disallowed medications.

Study Design

Total Participants: 474
Study Start date:
October 01, 2009
Estimated Completion Date:
February 28, 2011

Connect with a study center

  • Bausch & Lomb Incorporated

    Rochester, New York 14609
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.